Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab，Trastuzumab and SOX in the adjuvant treatment of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)
HER2-positive Gastric Cancer
DRUG: Serplulimab|DRUG: Trastuzumab|DRUG: Oxaliplatin + Tegafur
Disease progression free survival （DFS）, Objective response rate according to RECIST 1.1, 24 months after the last subject participating in
Overall survival (OS）, Overall survival, 24 months after the last subject participating in|Recurrence rate, Objective response rate according to RECIST 1.1, 24 months after the last subject participating in|Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE, Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE, through study completion, an average of 1 year
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab，Trastuzumab and SOX in the adjuvant treatment of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)